PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
14668580-3	2004	Omapatrilat, a VasoPeptidase-inhibitor, selectively inhibits both Neutral-Endo-Peptidase (NEP) and ACE.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	99-102	
12745671-0	2003	Omapatrilat, an angiotensin-converting enzyme and neutral endopeptidase inhibitor, attenuates early atherosclerosis in diabetic and in nondiabetic low-density lipoprotein receptor-deficient mice.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	16-45	
12745671-1	2003	Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	26-55	
12745671-1	2003	Omapatrilat inhibits both angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP).	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	57-60	
11254898-0	2001	Omapatrilat, a dual angiotensin-converting enzyme and neutral endopeptidase inhibitor, prevents fatty streak deposit in apolipoprotein E-deficient mice.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	20-49	
16208151-9	2005	Omapatrilat conferred superior renoprotection in the diabetic apo E-KO mouse compared with quinapril in the context of greater renal ACE inhibition by omapatrilat than seen with quinapril, additional renal NEP inhibition and a modestly enhanced antihypertensive response.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	133-136	
16208151-12	2005	These results suggest that the anti-atherosclerotic effect conferred by omapatrilat treatment in the diabetic apo E-KO mouse is predominantly mediated by its capacity to inhibit local vascular ACE.	omapatrilat	72-83	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	193-196	
16208151-13	2005	By contrast, in the kidney, local renal ACE and NEP inhibition and the superior antihypertensive effect of omapatrilat all contribute to the renoprotective effect conferred by omapatrilat treatment in the diabetic apo E-KO mouse.	omapatrilat	176-187	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	40-43	
34304582-2	2021	Omapatrilat, a dual NEP inhibitor-ACE inhibitor, was a promising antihypertensive drug but failed in trials due to angioedema, an effect possibly caused by inhibition of both the N- and C-domains of ACE.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	34-37	
34304582-2	2021	Omapatrilat, a dual NEP inhibitor-ACE inhibitor, was a promising antihypertensive drug but failed in trials due to angioedema, an effect possibly caused by inhibition of both the N- and C-domains of ACE.	omapatrilat	0-11	angiotensin I converting enzyme (peptidyl-dipeptidase A) 1	Mus musculus	199-202